This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In case you missed it, this week we had news about roflumilast foam's efficacy in diverse hair types of seborrheic dermatitis, Lindus Health's new partnership to evaluate a benzoyl peroxide alternative, sonelokimab advancing to phase 3 for HS, and more.
The FDA is reviewing a supplemental New Drug Application (sNDA) for tapinarof cream, 1%, as a potential treatment for atopic dermatitis (AD) in adults and children two years of age and older, with Prescription Drug User Fee Act (PDUFA) action expected in the fourth quarter of calendar year 2024.
Dermatitis is an umbrella term that refers to a group of skin conditions that cause skin irritation, sensitivity, redness, and similar symptoms. As the name implies, eyelid dermatitis or eyelid eczema, is a form of dermatitis that impacts the upper or lower eyelid. What is Eyelid Dermatitis?
The WHO Foundation and the LOral Groupe , spearheaded by its Dermatological Beauty Division, are launching a four-year partnership to expand access to the treatment of skin conditions worldwide.
2023 Childhood Eczema Challenge Grant – Supported in partnership with the National Eczema Association (NEA) Hassan Vahidnezhad, MSc, PhD of Children’s Hospital of Philadelphia, will conduct a project titled “ Genetic Landscape of Pediatric Patients with Monogenic Susceptibilities to Atopic Dermatitis.
Clinique has made a philanthropic commitment of $5 million over seven years for the advancement and evolution of allergy science through the partnership and founding of the Mount Sinai-Clinique Healthy Skin Dermatology Center. Years of chronic inflamed skin plays a role in premature aging.
“The team has generated a strong preclinical data package that builds on the scientific community’s growing understanding of PKM2 and its role in the pathogenesis of atopic dermatitis,” says Lain Kilty, Chief Scientific Officer of Sitryx, in a news release.
New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Suggest the usage of crisaborole 2% ointment for mild to moderate atopic dermatitis. in a news release. “It
The award will support a project titled “Paving the Way towards Meaningful Partnerships: Fostering Regional PCOR to Enhance Eczema Outcomes.” NEA will develop regional engagement frameworks highlighting patient partnerships to guide future eczema PCOR and CER applicable to a diverse patient population.
Mr. Raducha-Grace recently served as Head of Clinical Partnerships at Harbor Health. The company is also conducting a 250-patient phase 2b trial of its topical JAK 1/3 inhibitor, called ATI-1777 in atopic dermatitis. Before Harbor Health, he led product and go-to-market functions for CVS’s kidney care and home business units.
Many dermatologists advise against the use of over-the-counter antibiotic ointments like Neosporin (bacitracin + neomycin + polymyxin B) or other triple-antibiotic ointments, as these agents are commonly associated with allergic skin reactions and contact dermatitis. When to See a Dermatologist?
STAT6 is the specific transcription factor required for interleukin (IL)-4 and IL-13 cytokine signaling, which are clinically validated targets for T helper 2 (Th2) mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD, among many others.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content